• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Conatus Pharmaceuticals Inc

+ Add to Watchlist

CNAT:US

6.1500 USD 0.0800 1.32%

As of 14:32:09 ET on 09/30/2014.

Snapshot for Conatus Pharmaceuticals Inc (CNAT)

Open: 6.0300 Day's Range: 5.8500 - 6.3600 Volume: 114,456
Previous Close: 6.0700 52wk Range: 5.0600 - 15.6700 1-Yr Rtn: -38.81%

Stock Chart for CNAT

No chart data available.
  • CNAT:US 6.1000
  • 1D
  • 1M
  • 1Y
6.0700
Interactive CNAT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CNAT

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.2900
Est. EPS (USD) (12/2014) -1.6080
Est. PEG Ratio -
Market Cap (M USD) 95.71
Shares Outstanding (M) 15.66
30 Day Average Volume 232,330
Price/Book (mrq) 2.1890
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/14/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CNAT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CNAT

Conatus Pharmaceuticals, Inc. develops therapeutics to treat liver disease. The Company offers drugs to control programmed cell death that contributes to a range of liver diseases and cancer treatments. Conatus Pharmaceuticals provides its products in the United States.

Steven J MentoPresident/CEO/Co-FounderCharles J CashionSenior VP:Finance/CFO/Secy
Gary Craig BurgessSenior VP:Clinical/Chief Medical OfcrAlfred P SpadaSenior VP:R&D/Chief Scientific Ofcr
More Company Profile & Key Executives for CNAT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil